Ivy Leaf — Benefits Deep Dive

Ivy leaf has an unusual profile for a herb. Most herbal cough remedies rest on tradition and a handful of small studies. Ivy leaf extract, by contrast, has dozens of published clinical reports, observational studies covering tens of thousands of patients, a European Union monograph that places it under well-established use, and a widely quoted molecular mechanism. On paper it looks like one of the best-supported herbs on this site.

Look closer and the picture is more modest. The independent systematic reviewers who examined the trials rated their quality as low and their risk of bias as high, and judged the effect on cough to be "minimal at best". Placebo-controlled trials in children are few and small, and one of the better-designed ones missed its primary outcomes. The mechanism comes from cell experiments with a compound that is barely detectable in human blood. And the regulator that approved the extract also contraindicates it in children under two.

These four pages set out what each part of that record actually shows: the trials, the mechanism, the safety findings, and how ivy compares with thyme and the other cough herbs it is so often combined with.

Deep-Dive Articles

📊

Cough Trials in Adults and Children

Every major study type behind ivy leaf, from the 9,657-patient postmarketing study with no comparison group to the placebo-controlled asthma crossover trial in 30 children that missed its primary outcomes. What the independent systematic review concluded, why "everyone improved" is not evidence for a cough medicine, and where the placebo-controlled data are thinnest.

Read the deep dive →
🔬

Alpha-Hederin and the Beta2 Mechanism

The cell experiment behind the most-repeated explanation of how ivy works: alpha-hederin kept beta2 receptors on the cell surface, while the leaf's main saponin did nothing. Why the absorption data leave a gap between dish and patient, why the EU monograph still lists the mechanism as unknown, and what the large anti-cancer literature on alpha-hederin does and does not mean.

Read the deep dive →
⚠️

Safety in Children and Allergy

The European contraindication under two years of age and the reason given for it, the medical-diagnosis requirement for ages two to four, the gastrointestinal and allergic reactions reported, an accidental overdose in a four-year-old, occupational asthma, the gardener's rash from fresh sap, and the poisonous berries.

Read the deep dive →
🌿

Ivy Leaf vs Thyme and Other Cough Herbs

Ivy is rarely tested alone against another herb. What the reviews say about thyme, the thyme–ivy combination, Pelargonium, marshmallow, honey and Shirazi thyme, why a review of children's herbal medicines ranked another extract above ivy, and why "non-inferior to ivy" in a new trial says nothing about placebo.

Read the deep dive →

Table of Contents

  1. Deep-Dive Articles
  2. The Honest Position, in One Page
  3. Evidence Ledger at a Glance
  4. What the EU Monograph Says
  5. Key Research: Adult Trials and Systematic Reviews
  6. Key Research: Children and Asthma
  7. Key Research: Saponins and the Beta2 Receptor
  8. Key Research: Safety and Allergy
  9. Key Research: Comparators and Combinations
  10. External Resources
  11. Connections

The Honest Position, in One Page

What is solid

What is not

The conclusion that matters most

The volume of ivy leaf research is large, but most of it comes from studies that cannot show cause and effect: open studies with no comparison group, in an illness (acute bronchitis after a cold) that gets better on its own. When independent reviewers restrict themselves to the controlled trials, the effect shrinks to something that is measurable but of uncertain importance to patients. That is not the same as "it does not work" — it is a finding of small effects measured badly.

The real hazards

For the extract: use in infants, where European regulators judge that loosening mucus can worsen breathing; and delay, when a cough with breathlessness, fever or pus-like sputum is treated as a simple cough. For the plant: skin contact with sap, and children eating the berries.

Evidence Ledger at a Glance

Ranked by how well established each item is. "Negative" and "absent" are listed separately because they are different verdicts.

  1. Established, regulatory: EU well-established use as an expectorant for productive cough; contraindicated under age two; not recommended in pregnancy and breastfeeding for lack of data.
  2. Established, human, observational: low short-term adverse-event rates, mainly gastrointestinal, in very large uncontrolled cohorts.
  3. Established, chemical: the saponin profile and the hederacoside C marker.
  4. Small positive effects, human, high risk of bias: faster reduction in cough severity or frequency in three adult randomised trials, of minimal clinical significance according to an independent systematic review.
  5. Single small positive trial, children: ivy leaf drops reduced airway resistance compared with placebo in one paediatric trial, p = 0.04.
  6. Negative on primary outcomes, children: add-on ivy leaf extract in 30 children with asthma on inhaled steroids did not change the primary lung-function measures.
  7. Equivalence without placebo, human: an ivy-plus-Coptis combination matched ivy extract alone in a 236-patient phase 3 trial.
  8. Reproducible, laboratory: alpha-hederin, but not hederacoside C or hederagenin, alters beta2-receptor internalisation and binding in human cell lines.
  9. Laboratory and animal only: antispasmodic, anti-inflammatory and secretory effects in isolated tissue and animals; anti-cancer effects of alpha-hederin in cell cultures and mice.
  10. Gap, human: oral absorption of alpha-hederin is low in rats and near-undetectable in small human studies.
  11. Absent: large, independent, placebo-controlled trials in children; long-term use data; pregnancy, fertility, genotoxicity and carcinogenicity data.

What the EU Monograph Says

The current European Union herbal monograph on ivy leaf (EMA/HMPC/325716/2017, adopted 21 November 2017) is the most authoritative single summary of the medicine's regulatory status. Its main statements, reported as written:

Key Research: Adult Trials and Systematic Reviews

  1. Sierocinski E, Holzinger F, Chenot JF. Ivy leaf (Hedera helix) for acute upper respiratory tract infections: an updated systematic review. European journal of clinical pharmacology. 2021;77(8):1113-1122. PubMed PMID: 33523253 — independent update: 6 randomised trials, 1 controlled trial, 4 observational studies; effects "minimal at best", high risk of bias.
  2. Pawłowska AM. From Traditional Remedy to Evidence-Based Phytotherapeutic Agent: Hedera helix L. in Respiratory Medicine. Plants (Basel, Switzerland). 2026;15(17). PubMed PMID: 42739377 — a quality-to-clinic evidence map covering chemistry, absorption, toxicology, trials and regulation.
  3. Baharara H, Moghadam AT, Sahebkar A, et al. The Effects of Ivy (Hedera helix) on Respiratory Problems and Cough in Humans: A Review. Advances in experimental medicine and biology. 2021;1328:361-376. PubMed PMID: 34981489 — a narrative review of tablet and liquid forms in respiratory problems; notes the Commission E approval.
  4. Fazio S, Pouso J, Dolinsky D, et al. Tolerance, safety and efficacy of Hedera helix extract in inflammatory bronchial diseases under clinical practice conditions: a prospective, open, multicentre postmarketing study in 9657 patients. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2009;16(1):17-24. PubMed PMID: 16860549 — 9,657 patients in routine practice, no comparison group; 2.1% adverse events.
  5. Cho YJ, Yoon HJ, Lim DH, et al. Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms. Journal of Korean medical science. 2026;41(9):e97. PubMed PMID: 41807028 — ivy leaf extract as the active comparator in a 236-patient non-inferiority trial.

Key Research: Children and Asthma

  1. Hofmann D, Hecker M, Völp A. Efficacy of dry extract of ivy leaves in children with bronchial asthma--a review of randomized controlled trials. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2003;10(2-3):213-20. PubMed PMID: 12725580 — three paediatric trials, only one with placebo; a single significant result on airway resistance.
  2. Zeil S, Schwanebeck U, Vogelberg C. Tolerance and effect of an add-on treatment with a cough medicine containing ivy leaves dry extract on lung function in children with bronchial asthma. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2014;21(10):1216-20. PubMed PMID: 24916707 — double-blind crossover in 30 children; no effect on the primary outcomes.
  3. Seifert G, Upstone L, Watling CP, et al. Ivy leaf dry extract EA 575 for the treatment of acute and chronic cough in pediatric patients: review and expert survey. Current medical research and opinion. 2023;39(10):1407-1417. PubMed PMID: 37731370 — 10 controlled and 9 observational studies of one extract in children; more robust trials called for.
  4. Kamin W, Seifert G, Zwiauer K, et al. Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review. Frontiers in pediatrics. 2025;13:1423250. PubMed PMID: 40376625 — 45 reports, only nine double-blind and placebo-controlled; further research needed for ivy.

Key Research: Saponins and the Beta2 Receptor

  1. Sieben A, Prenner L, Sorkalla T, et al. Alpha-hederin, but not hederacoside C and hederagenin from Hedera helix, affects the binding behavior, dynamics, and regulation of beta 2-adrenergic receptors. Biochemistry. 2009;48(15):3477-82. PubMed PMID: 19278262 — the founding cell experiment: alpha-hederin, but not hederacoside C or hederagenin, altered beta2-receptor behaviour.
  2. Belmehdi O, Taha D, Abrini J, et al. Anticancer properties and mechanism insights of α-hederin. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023;165:115205. PubMed PMID: 37499451 — review of alpha-hederin's anti-cancer activity in laboratory models.
  3. Jeong KB, Luo K, Lee H, et al. Alpha-Hederin Nanopore for Single Nucleotide Discrimination. ACS nano. 2019;13(2):1719-1727. PubMed PMID: 30657663 — how alpha-hederin forms pores in cholesterol-rich membranes, the basis of its toxicity to cells.

Key Research: Safety and Allergy

  1. Hannu T, Kauppi P, Tuppurainen M, et al. Occupational asthma to ivy (Hedera helix). Allergy. 2008;63(4):482-3. PubMed PMID: 18315739 — a report of occupational asthma caused by ivy.
  2. Fazio S, Pouso J, Dolinsky D, et al. Tolerance, safety and efficacy of Hedera helix extract in inflammatory bronchial diseases under clinical practice conditions: a prospective, open, multicentre postmarketing study in 9657 patients. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2009;16(1):17-24. PubMed PMID: 16860549 — the largest tolerability dataset, with gastrointestinal events at 1.5%.
  3. Seifert G, Upstone L, Watling CP, et al. Ivy leaf dry extract EA 575 for the treatment of acute and chronic cough in pediatric patients: review and expert survey. Current medical research and opinion. 2023;39(10):1407-1417. PubMed PMID: 37731370 — low adverse-event rates in children, including infants, in one extract's studies.

Key Research: Comparators and Combinations

  1. Ciprandi G, Tosca MA. Non-pharmacological remedies for post-viral acute cough. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace. 2021;92(1). PubMed PMID: 34461702 — "some evidence" for ivy, thyme, honey, marshmallow, Pelargonium and others in post-viral cough.
  2. Silveira D, Prieto-Garcia JM, Boylan F, et al. COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy? Frontiers in pharmacology. 2020;11:581840. PubMed PMID: 33071794 — a benefit–risk assessment rating ivy "positive" alongside marshmallow, licorice, myrrh and elder.
  3. Mahboubi M. Management of acute cough by Zataria multiflora Boiss as an alternative treatment. Journal of integrative medicine. 2018;16(1):20-25. PubMed PMID: 29397088 — Shirazi thyme (Zataria multiflora) in acute cough, with a proposal to test it alongside ivy.
  4. Khan M, Rehman H, Naveed S, et al. Chewable cough tablets with improved palatability: A comparative phase II clinical trial. Pakistan journal of pharmaceutical sciences. 2019;32(1(Supplementary)):339-343. PubMed PMID: 30829213 — a chewable tablet combining marshmallow root, ivy leaf and Sisymbrium irio seed against another multi-herb product.

External Resources

Connections

Back to Table of Contents